aTyr Pharma
ATYR
102 hedge funds and large institutions have $51.5M invested in aTyr Pharma in 2025 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 39 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 25
7% less funds holding
Funds holding: 110 → 102 (-8)
11.35% less ownership
Funds ownership: 74.56% → 63.21% (-11%)
15% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 39
27% less capital inflows, than outflows
Capital inflows: $69.5M | Capital outflows: $94.5M
60% less call options, than puts
Call options by funds: $3.95M | Put options by funds: $10M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.4M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$12.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.11M |
| 4 |
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$4.71M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Octagon Capital Advisors
New York
|
-$19.4M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$18.7M |
| 3 |
TM
Tikvah Management
Charlotte,
North Carolina
|
-$9.06M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$7.16M |
| 5 |
Woodline Partners
San Francisco,
California
|
-$7.15M |
ATYR Hedge Fund Activity: Q3 2025 in Review
102 of the 7,652 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2025, worth a combined $51.5M — down 85% from $336M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of ATYR and 33 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 32 added.
The largest buyer was State Street, adding an estimated $13.4M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $19.4M sold.
- 102 institutional investors held aTyr Pharma (ATYR) as of Q3 2025, down from 110 in Q2 2025.
- Funds reported $51.5M of aTyr Pharma stock for Q3 2025, down 85% quarter-over-quarter.
- 33 funds opened new aTyr Pharma positions in Q3 2025 and 39 closed out, a net change of -6 holders.
- The largest aTyr Pharma buyer in Q3 2025 was State Street, an estimated $13.4M added.
- The largest aTyr Pharma seller in Q3 2025 was Octagon Capital Advisors, an estimated $19.4M sold.
Based on aggregated 13F filings for Q3 2025.